BLLN BillionToOne, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

—

Period return

—

Volume

—

There isn’t enough historical data to display yet.

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 05.Highin 15 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — SOROS FUND MANAGEMENT LLC
신규 편입 · 포트폴리오 비중 0.02%
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.01%
2026. 05. 13.LowBUY2 months ago
Guggenheim: Buy
US analyst rating / recommendation change.
2026. 05. 08.LowBUY3 months ago
JP Morgan: Overweight
US analyst rating / recommendation change.
2026. 05. 07.LowBUY3 months ago
BTIG: Buy
US analyst rating / recommendation change.
2026. 03. 31.LowBUY4 months ago
Guggenheim: Buy
US analyst rating / recommendation change.
2026. 03. 06.LowHOLD5 months ago
Wells Fargo: Equal-Weight
US analyst rating / recommendation change.
2026. 03. 05.LowBUY5 months ago
Guggenheim: Buy
US analyst rating / recommendation change.
2026. 03. 05.LowBUY5 months ago
BTIG: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $117.71 · 7 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.

Sector: Healthcare
Industry: Diagnostics & Research
HQ: Menlo Park, CA, United States
Fiscal year end: —
Employees: 713
IPO date: —

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 05.	After market close (AMC)	$0.16	—	—	$109.12M	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$-0.39	—	—	$58.96M	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$-2.99	—	—	$107.51M	Reported

BillionToOne, Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 13.	Guggenheim	—	Maintain	Buy → Buy	—	Guggenheim: Buy
2026. 05. 08.	JP Morgan	—	Maintain	Overweight → Overweight	—	JP Morgan: Overweight
2026. 05. 07.	BTIG	—	Maintain	Buy → Buy	—	BTIG: Buy
2026. 03. 31.	Guggenheim	—	Maintain	Buy → Buy	—	Guggenheim: Buy
2026. 03. 06.	Wells Fargo	—	Maintain	Equal-Weight → Equal-Weight	—	Wells Fargo: Equal-Weight
2026. 03. 05.	Guggenheim	—	Maintain	Buy → Buy	—	Guggenheim: Buy

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	82,776	$6.53M	0.01%	—	New position
2	SOROS FUND MANAGEMENT LLC	SOROS FUND MANAGEMENT LLC	14,500	$1.19M	0.02%	—	New position
3	SOROS FUND MANAGEMENT LLC	SOROS FUND MANAGEMENT LLC	14,500	$1.14M	0.02%	—	New position